MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study
Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-mediated MDR. In the present study, we reported for...
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Elsevier
2022-05-01
|
| 叢編: | Acta Pharmaceutica Sinica B |
| 主題: | |
| 在線閱讀: | http://www.sciencedirect.com/science/article/pii/S2211383521004901 |